Overall asthma control: The relationship between current control and future risk

Research output: Contribution to journalArticle

Bibtex

@article{02107fadd4744431afd620e963964d18,
title = "Overall asthma control: The relationship between current control and future risk",
abstract = "Background: Asthma guidelines emphasize both maintaining current control and reducing future risk, but the relationship between these 2 targets is not well understood. Objective: This retrospective analysis of 5 budesonide/formoterol maintenance and reliever therapy (Symbicort SMART Turbuhaler*) studies assessed the relationship between asthma control questionnaire (ACQ-5) and Global Initiative for Asthma-defined clinical asthma control and future risk of instability and exacerbations. Methods: The percentage of patients with Global Initiative for Asthma defined controlled asthma over time was assessed for budesonide/formoterol maintenance and reliever therapy versus the 3 maintenance therapies; higher dose inhaled corticosteroid (ICS), same dose ICS/long-acting beta(2)-agonist (LABA), and higher dose ICS/LABA plus short-acting beta(2)-agonist. The relationship between baseline ACQ-5 and exacerbations was investigated. A Markov analysis examined the transitional probability of change in control status throughout the studies. Results: The percentage of patients achieving asthma control increased with time, irrespective of treatment; the percentage Controlled/Partly Controlled at study end was at least similar to budesonide/formoterol maintenance and reliever therapy versus the 3 maintenance therapies: higher dose ICS (56{\%} vs 45{\%}), same dose ICS/LABA (56{\%} vs 53{\%}), and higher dose ICS/LABA (54{\%} vs 54{\%}). Baseline ACQ-5 score correlated positively with exacerbation rates. A Controlled or Partly Controlled week predicted at least Partly Controlled asthma the following week (>= 80{\%} probability). The better the control, the lower the risk of an Uncontrolled week. The probability of an exacerbation was related to current state and was lower with budesonide/formoterol maintenance and reliever therapy. Conclusions: Current control predicts future risk of instability and exacerbations. Budesonide/formoterol maintenance and reliever therapy reduces exacerbations versus comparators and achieves at least similar control. (J Allergy Clin Immunol 2010;125:600-8.)",
keywords = "exacerbations, Asthma control, ACQ, GINA",
author = "Bateman, {Eric D.} and Reddel, {Helen K.} and G{\"o}ran Eriksson and Stefan Peterson and Ollie Ostlund and Sears, {Malcolm R.} and Christine Jenkins and Marc Humbert and Roland Buhl and Harrison, {Tim W.} and Santiago Quirce and O'Byrne, {Paul M.}",
year = "2010",
doi = "10.1016/j.jaci.2009.11.033",
language = "English",
volume = "125",
pages = "600--608",
journal = "Journal of Allergy and Clinical Immunology",
issn = "1097-6825",
publisher = "Elsevier",
number = "3",

}